Gluetacs focuses on clinically unmet needs, leveraging science and technology to bring precision treatments to patients. Our company is currently developing innovative protein degrader drugs targeting multiple indications. Specifically, its ongoing project for hematological malignancies (multiple myeloma and non-Hodgkin's lymphoma) has progressed to Phase I clinical trials, aiming to overcome drug resistance in relapsed and refractory patients with these conditions and urgently address the lack of effective therapies for such patients.

In parallel, Gluetacs attaches great importance to the development of drugs for solid tumors, including lung cancer, liver cancer, colorectal cancer, gastric cancer, and more. Grounded in the epidemiology of cancer in China, the company continually explores and develops innovative therapies tailored to the national context. Rather than categorizing tumors as the sole basis for drug development, Gluetacs adopts a strategy that transcends tumor types. Instead, it relies on biological, epidemiological, and basic medical research to break through the limitations of specific cancer types, providing more precise treatments for solid tumors based on their biological and clinical characteristics.

Addressing autoimmune diseases, a global challenge, Gluetacs leverages its unique dual platforms of molecular glue and GLUETAC protein degradation technology to continuously explore breakthroughs in treatment.